ACM-001 is under clinical development by Actimed Therapeutics and currently in Phase II for Cancer Anorexia-Cachexia Syndrome. According to GlobalData, Phase II drugs for Cancer Anorexia-Cachexia Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ACM-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Espindolol (ACM-001) is under development for the treatment of cachexia related to stage III and IV non-small cell lung cancer, colorectal cancer and muscle weakness due to muscle weakness. It is administered orally as a tablet. It is a dual action anabolic catabolic transforming agent (ACTA). The drug candidate targets 5-HT1A, adrenergic beta-1 and beta-2 receptor. It was also under development for the treatment of sarcopenia.
Actimed Therapeutics overview
Actimed Therapeutics (Actimed) is a clinical-stage biopharmaceutical business focusing on bringing innovation to the treatment a disease called cachexia which is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality and despite its prevalence and devastating clinical effects, there is no globally approved pharmaceutical product for the treatment or prevention of cancer-related cachexia. The company’s pipeline products include S-pindolol benzoate (ACM-001.1)S-oxprenolol (ACM-002) consists of multi-action agents that affect more than one pathway critical to the development of cachexia. It operates in the UK. Actimed is headquartered in Berkshire, England, the Uk.
For a complete picture of ACM-001’s drug-specific PTSR and LoA scores, buy the report here.